Poolbeg Pharma identifies potential new drug candidates for RSV infections

RSV is one of three main respiratory illnesses for which there are no approved vaccines

Pictured Jeremy Skillington, Chief Executive Officer at Poolbeg Pharma. Picture Jason Clarke

Irish biotech company Poolbeg Pharma has announced today that it has identified potential new drug candidates for respiratory syncytial virus (RSV) infections.

In a collaboration with US firm, OneThree Biotech, the two companies joined forces in February this year, with Poolbeg today revealing that they have determined mutiple drug targets for the treatment of RSV.